Thymosin Alpha‑1 is a synthetic 28‑amino‑acid peptide originally produced by the thymus gland. It has been approved in more than 35 countries for hepatitis B and C and is promoted as a general immune enhancer, though it lacks FDA approval in the United States. Dr. Jason Schuster highlights its potential to reshape how we support immunity and fight disease.
A Short Peptide from the Thymus
Thymosin Alpha‑1 is a 28‑amino‑acid chain derived from the thymus, synthesized for medical use. While its counterpart Thymosin Beta‑4 is 43 amino acids long, Alpha‑1 is the shorter, more specific peptide discussed by Dr. Schuster.
- 28‑acid peptide produced naturally by the thymus
- Synthetic form available for clinical use
- Approved in >35 countries for hepatitis B/C and as an immune enhancer
- Not FDA‑approved; held orphan‑drug status in the US (1991‑2006)
How It Talks to the Immune System
According to Dr. Schuster, Thymosin Alpha‑1 enhances innate immunity by boosting T‑cell activity and natural killer (NK) cell function, creating a more robust antiviral and anti‑cancer response without the broad toxicity of chemotherapy.
- Enhances T‑cell function in human and animal studies
- Amplifies natural killer cell activity
- Modulates cytokine responses for better viral clearance
Clinical Areas Studied
The video cites several peer‑reviewed investigations showing Thymosin Alpha‑1’s impact across infectious, oncologic, and autoimmune contexts.
- Improves outcomes in hepatitis B and C treatment
- Systematic review (2023, 8 studies) showed significantly lower mortality in moderate‑to‑critical COVID‑19 patients
- Demonstrated anti‑cancer activity in hepatocellular carcinoma, malignant melanoma, and DiGeorge syndrome
- Potent antiviral effects noted in multiple human and animal models
Low Risk, High Reward
Dr. Schuster emphasizes that meta‑analyses report virtually no severe adverse reactions or toxicity. Over 500,000 Americans have received the peptide through 503A compounding pharmacies without reported serious side effects.
- 2024 meta‑analysis: zero severe adverse reactions or toxicity
- Prescribed to >500,000 U.S. patients via compounded formulations
- Dosing guidelines are typically provided by compounding pharmacies; the video does not specify exact doses
“Zero severe adverse reactions or toxicity have been observed in meta‑analyses of Thymosin Alpha‑1.”— Dr. Jason Schuster
Dr. Schuster's short takes on this topic — tap to play.
Go deeper than the summary
Dr. Schuster's accredited courses on supplementation, epigenetics, and peptide therapy — the full research, dosing, and video breakdowns.